N-Formyl Vortioxetine Impurity Control in Solid Preparations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The presence of an unknown impurity in vortioxetine solid preparations, exceeding 0.5% under uncontrolled conditions, poses a challenge for the safety, effectiveness, and quality control of vortioxetine hydrobromide tablets and sustained-release tablets, necessitating the identification of the impurity's structure and a method for its preparation.
Innovation Solution
The discovery of N-formyl vortioxetine as a new impurity, characterized by its molecular formula and NMR data, along with a method involving the reaction of vortioxetine with a formylating agent under controlled conditions to produce the impurity, which is then used as a reference for quality control and stability research.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vortioxetine solid preparation is stored under high temperature or high humidity conditions, then the secondary amine in piperazine ring undergoes rearrangement reactions with excipients, but this results in the formation of N-formyl vortioxetine impurity exceeding acceptable limits
Solution Approach 1:
The patent applies preliminary action by conducting stability studies under accelerated conditions (high temperature and humidity) before final product formulation to identify potential impurity formation. This allows the研发团队 to proactively adjust formulation or storage conditions to prevent N-formyl vortioxetine impurity formation above 0.2% threshold
Solution Approach 2:
The patent employs parameter changes by modifying storage conditions (temperature, humidity) and formulation parameters to control the rearrangement reaction. By optimizing these parameters, the patent maintains drug stability while minimizing impurity formation to acceptable levels
2Manufacturing precision
If the content of N-formyl vortioxetine impurity is reduced to below 0.2%, then quality control standards are met, but this requires precise control of preparation conditions and stability parameters
Solution Approach 1:
The patent implements feedback mechanisms through comprehensive quality control testing that monitors N-formyl vortioxetine impurity levels. By measuring impurity content and adjusting preparation parameters based on these measurements, the patent achieves precise control to maintain impurity levels below 0.2%
Solution Approach 2:
The patent replaces complex mechanical control systems with chemical and analytical solutions. Instead of using complex equipment to prevent impurity formation, the patent relies on controlled chemical reactions and analytical methods (HPLC, NMR, MS) to detect and quantify impurities, simplifying the overall control system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method allows for the production of N-formyl vortioxetine with high purity and controlled content, reducing impurity levels in vortioxetine solid preparations, enhancing stability and quality control, and ensuring the safety and effectiveness of the drug.
Implementation Method 1
the secondary amine in piperazine ring of vortioxetine easily undergoes rearrangement reactions with reducing sugar excipients contained in the prescription or excipients such as cellulose or cellulose derivatives, thereby attaching a formyl group to the secondary amine group
Implementation Method 2
the secondary amine in piperazine ring of vortioxetine easily undergoes rearrangement reactions with reducing sugar excipients contained in the prescription
Implementation Method 3
its [M+H+] accurate molecular weight is 327.1535, as determined by high resolution mass spectrometry (HRMS) with a matching error of 2.75 ppm
Implementation Method 4
The1H-NMR and 13C-NMR data of N-formyl vortioxetine are summarized in Tables 1 and 2
Data Source
AI summary
Disclosed is N-formyl vortioxetine, and also disclosed is a method for preparing the N-formyl vortioxetine and a stable solid preparation of vortioxetine.